Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma

Basit Öğe Kaydı
dc.authoridMUZ, Dilek/0000-0001-9358-8103
dc.authoridERDAL, BERNA/0000-0003-3375-7926
dc.contributor.authorYesilaltay, Alpay
dc.contributor.authorMuz, Dilek
dc.contributor.authorErdal, Berna
dc.contributor.authorBilgen, Turker
dc.contributor.authorBatar, Bahadir
dc.contributor.authorTurgut, Burhan
dc.contributor.authorTopcu, Birol
dc.date.accessioned2024-10-29T17:59:25Z
dc.date.available2024-10-29T17:59:25Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractThis study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, and bortezomib were used in MM cells. The cytotoxicity assay was investigated using WST-1. Apoptosis was assessed through flow cytometry with Annexin V/PI staining and caspase-9 concentrations using ELISA. To explore MYXV entry into MM cells, monoclonal antibodies were used. Moreover, to explore the mechanisms of MYXV entry into MM cells, we examined the level of GFP-labeled MYXV within the cells after blocking with monoclonal antibodies targeting BCMA, CD20, CD28, CD33, CD38, CD56, CD86, CD117, CD138, CD200, and CD307 in MM cells. The study demonstrated the effects of treating Myxoma virus with lenalidomide and bortezomib. The treatment resulted in reduced cell viability and increased caspase-9 expression. Only low-dose CD86 blockade showed a significant difference in MYXV entry into MM cells. The virus caused an increase in the rate of apoptosis in the cells, regardless of whether it was administered alone or in combination with drugs. The groups with the presence of the virus showed higher rates of early apoptosis. The Virus, Virus + Bortezomib, and Virus + Lenalidomide groups had significantly higher rates of early apoptosis (p < 0.001). However, the measurements of late apoptosis and necrosis showed variability. The addition of MYXV resulted in a statistically significant increase in early apoptosis in both newly diagnosed and refractory MM patients. Our results highlight that patient-based therapy should also be considered for the effective management of MM.
dc.description.sponsorshipThe Scientific and Technological Research Council of Trkiye (TBIdot;TAK)
dc.description.sponsorshipWe thank Eric Bartee for providing us with the Myxoma virus necessary for our study.
dc.identifier.doi10.3390/pathogens13010072
dc.identifier.issn2076-0817
dc.identifier.issue1en_US
dc.identifier.pmid38251379
dc.identifier.scopus2-s2.0-85183155781
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/pathogens13010072
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14731
dc.identifier.volume13
dc.identifier.wosWOS:001152756200001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofPathogens
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectmultiple myeloma
dc.subjectoncolytic virus
dc.subjectmyxoma virus
dc.subjectlenalidomide
dc.subjectbortezomib
dc.titleMyxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu